{"id":"W3033430185","doi":"10.1136/annrheumdis-2020-eular.1229","title":"OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Psoriatic arthritis; Rheumatoid arthritis; Psoriasis; Internal medicine; Clinical endpoint; Adverse effect; Certolizumab pegol; Placebo; Randomized controlled trial; Psoriasis Area and Severity Index; Dermatology; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001675065,0.001980001,0.003663836,0.0004349776,0.0004296954,0.001477858,0.0008876121,0.001813741,0.007347579],"category_scores_gemma":[0.001436728,0.000690228,0.002464627,0.0005300046,0.001276127,0.001521829,0.0003842236,0.003066231,0.001258687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006054092,"about_ca_system_score_gemma":0.0009579103,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007101839,"about_ca_topic_score_gemma":0.001691869,"domain_scores_codex":[0.9994248,0.0002707582,0.00003579762,0.000101525,0.00005021331,0.0001169737],"domain_scores_gemma":[0.9992643,0.000216541,0.0001610924,0.00005930796,0.00004649904,0.0002523681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787717,0.003267101,0.0004396087,0.0006105773,0.001158343,0.00004309398,0.00003137203,0.0003093404,0.00163758,0.00008696063,0.0008130568,0.0128312],"study_design_scores_gemma":[0.9515548,0.04526667,0.001368106,0.00002951773,0.0005938624,0.000046585,0.0000176818,0.0003792249,0.0002729417,0.0001112285,0.000340686,0.00001884789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859065,0.007031124,0.0005903236,0.0005638605,0.0004502284,0.00182425,0.00118976,0.0001953724,0.002248605],"genre_scores_gemma":[0.9910749,0.002593987,0.0006999749,0.0007956817,0.0003374968,0.001561476,0.001082416,0.00002711942,0.001826831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007347579,"threshold_uncertainty_score":0.02458012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03676498366221415,"score_gpt":0.3273892182260358,"score_spread":0.2906242345638217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}